Eton Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Eton Pharmaceuticals reports significant revenue growth in 2025 driven by product sales, despite an increased net loss and ongoing R&D investments.
NASDAQ
Eton Pharmaceuticals' 10-K filing reveals a year of revenue growth and strategic acquisitions, alongside a necessary accounting adjustment for the INCRELEX acquisition.
NASDAQ
Eton Pharmaceuticals has filed an amendment to its annual report to correct the consent of its independent accounting firm, with no other changes to the original filing.
NASDAQ
Eton Pharmaceuticals has adopted a clawback policy to recoup executive incentive compensation in the event of an accounting restatement due to material noncompliance with financial reporting requirements.